

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0104 |
| Estimated average burden hours per response: | 0.5 |

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | |
|--|---|---|---|
| 1. Name and Address of Reporting Person* <u>Northpond Ventures III GP, LLC</u> (Last) (First) (Middle) 7500 OLD GEORGETOWN ROAD, SUITE 800 (Street) BETHESDA MD 20814 (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) 02/07/2024 | 3. Issuer Name and Ticker or Trading Symbol <u>Kyverna Therapeutics, Inc.</u> [KYTX] | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) | 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
|---------------------------------|---|--|---|

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|----------------------------|--|--|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Series B Preferred Stock | (1) | (1) | Common Stock | 2,805,426 | (1) | I | By: Northpond Ventures III, LP ⁽²⁾ |

1. Name and Address of Reporting Person*
Northpond Ventures III GP, LLC
 (Last) (First) (Middle)
 7500 OLD GEORGETOWN ROAD, SUITE 800
 (Street)
 BETHESDA MD 20814
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Northpond Ventures III, LP
 (Last) (First) (Middle)
 7500 OLD GEORGETOWN ROAD, SUITE 800
 (Street)
 BETHESDA MD 20814
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Rubin Michael P.

| | | |
|-------------------------------------|---------|----------|
| (Last) | (First) | (Middle) |
| 7500 OLD GEORGETOWN ROAD, SUITE 800 | | |
| (Street) | | |
| BETHESDA | MD | 20814 |
| (City) | (State) | (Zip) |

Explanation of Responses:

- All shares of Series B Convertible Preferred Stock, par value \$0.00001 per share (the "Series B Preferred Stock"), of Kyverna Therapeutics, Inc. (the "Issuer") will automatically convert on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value \$0.00001 per share (the "Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Preferred Stock has no expiration date.
- Northpond Ventures III GP, LLC ("Northpond III LLC") is the general partner of Northpond Ventures III, LP ("Northpond Fund III"), and Michael P. Rubin is the managing member of Northpond III LLC. As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's respective pecuniary interest therein, if any.

| | |
|---|-------------------|
| <u>Northpond Ventures III GP, LLC, By: /s/ Patrick Smerkers, Chief Financial Officer</u> | <u>02/07/2024</u> |
| <u>Northpond Ventures III, LP, By: Northpond Ventures III GP, LLC, its general partner, By: /s/ Patrick Smerkers, Chief Financial Officer</u> | <u>02/07/2024</u> |
| <u>/s/ Michael P. Rubin</u> | <u>02/07/2024</u> |
| ** Signature of Reporting Person | Date |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.